Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, TVTX, LLY, MDGL, MIRM, and represent 31.07% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$45M), TVTX (+$40M), Avalyn Pharma (+$22M), Hemab Therapeutics Holdings (+$21M), Parabilis Medicines (+$16M), CYTK (+$12M), MMED (+$7.0M), OMER (+$6.8M), DFTX (+$6.7M), Mobia Med (+$5.6M).
- Started 17 new stock positions in SGMT, Parabilis Medicines, AXSM, Hemab Therapeutics Holdings, MDT, DFTX, TRVI, OMER, CAPR, Kailera Therapeutics. Avalyn Pharma, GKOS, NGEN, ASND, SYRE, ALT, Mobia Med.
- Reduced shares in these 10 stocks: Ascendis Pharma A S (-$44M), ARGX (-$42M), RVMD (-$20M), ACLX (-$20M), ELVN (-$18M), Centessa Pharmaceuticals (-$14M), AGIO (-$9.9M), Soleno Therapeutics (-$8.6M), RARE (-$8.4M), .
- Sold out of its positions in ACHC, FOLD, Apellis Pharmaceuticals, ACLX, Ascendis Pharma A S, Centessa Pharmaceuticals, EW, GOSS, REGN, XBI. Soleno Therapeutics, TERN, JAZZ.
- Rock Springs Capital Management was a net seller of stock by $-7.0M.
- Rock Springs Capital Management has $2.0B in assets under management (AUM), dropping by 20.76%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 104 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 10.1 | $207M | -8% | 1.1M | 187.28 |
|
| Travere Therapeutics (TVTX) | 6.0 | $124M | +47% | 2.2M | 56.81 |
|
| Eli Lilly & Co. (LLY) | 5.8 | $118M | 99k | 1199.43 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 4.6 | $94M | +2% | 175k | 536.95 |
|
| Mirum Pharmaceuticals (MIRM) | 4.6 | $93M | 798k | 117.07 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 3.8 | $77M | 693k | 111.03 |
|
|
| Kymera Therapeutics (KYMR) | 2.5 | $52M | -8% | 453k | 114.67 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.4 | $49M | -46% | 53k | 927.77 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 2.2 | $45M | NEW | 169k | 266.72 |
|
| Xenon Pharmaceuticals (XENE) | 2.0 | $41M | -10% | 684k | 60.36 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.9 | $39M | -3% | 716k | 55.00 |
|
| Insmed Com Par $.01 (INSM) | 1.9 | $39M | +15% | 362k | 106.62 |
|
| Penumbra (PEN) | 1.8 | $37M | -3% | 116k | 315.75 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.7 | $34M | 640k | 53.67 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 1.6 | $32M | -20% | 968k | 33.39 |
|
| Irhythm Technologies (IRTC) | 1.6 | $32M | +3% | 270k | 118.95 |
|
| Intuitive Surgical Com New (ISRG) | 1.5 | $30M | -6% | 77k | 397.68 |
|
| Agilon Health Com New (AGL) | 1.4 | $28M | 263k | 107.18 |
|
|
| UnitedHealth (UNH) | 1.3 | $27M | +20% | 64k | 415.63 |
|
| Celldex Therapeutics Com New (CLDX) | 1.3 | $26M | +7% | 699k | 37.21 |
|
| Erasca (ERAS) | 1.3 | $26M | +27% | 1.4M | 18.32 |
|
| Neurocrine Biosciences (NBIX) | 1.2 | $24M | -3% | 145k | 168.53 |
|
| Enliven Therapeutics (ELVN) | 1.2 | $24M | -43% | 465k | 50.75 |
|
| Tenet Healthcare Corp Com New (THC) | 1.1 | $23M | 125k | 187.08 |
|
|
| Dex (DXCM) | 1.1 | $23M | -3% | 343k | 67.35 |
|
| Aclaris Therapeutics (ACRS) | 1.1 | $23M | -3% | 4.3M | 5.29 |
|
| Minimed Group (MMED) | 1.1 | $23M | +44% | 1.5M | 14.95 |
|
| Boston Scientific Corporation (BSX) | 1.1 | $23M | +2% | 529k | 42.68 |
|
| Pharvaris N V (PHVS) | 1.1 | $22M | 648k | 34.58 |
|
|
| Avalyn Pharmaceuticals Com Shs | 1.1 | $22M | NEW | 663k | 32.92 |
|
| Hemab Therapeutics Hldgs Com Shs | 1.0 | $21M | NEW | 575k | 36.73 |
|
| Dyne Therapeutics (DYN) | 1.0 | $21M | -3% | 942k | 22.21 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.0 | $20M | -9% | 67k | 301.03 |
|
| Cogent Biosciences (COGT) | 1.0 | $20M | -17% | 516k | 38.70 |
|
| Agios Pharmaceuticals (AGIO) | 1.0 | $20M | -33% | 533k | 37.11 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $20M | 583k | 33.89 |
|
|
| Vera Therapeutics Cl A (VERA) | 0.9 | $18M | -15% | 428k | 42.91 |
|
| Tarsus Pharmaceuticals (TARS) | 0.9 | $17M | +23% | 277k | 62.94 |
|
| Heartflow Inc/Sh (HTFL) | 0.8 | $17M | 574k | 29.34 |
|
|
| Mbx Biosciences (MBX) | 0.8 | $17M | +3% | 298k | 55.20 |
|
| Cytokinetics Com New (CYTK) | 0.8 | $16M | +314% | 188k | 85.19 |
|
| Bicara Therapeutics (BCAX) | 0.8 | $16M | +9% | 535k | 29.69 |
|
| Parabilis Medicines | 0.8 | $16M | NEW | 578k | 27.37 |
|
| Zai Lab Adr (ZLAB) | 0.8 | $16M | 815k | 19.00 |
|
|
| Danaher Corporation (DHR) | 0.7 | $15M | +24% | 76k | 190.48 |
|
| Tango Therapeutics (TNGX) | 0.7 | $14M | +17% | 457k | 31.26 |
|
| Evolent Health Cl A (EVH) | 0.7 | $14M | -6% | 2.5M | 5.42 |
|
| Ptc Therapeutics I (PTCT) | 0.6 | $13M | 162k | 81.57 |
|
|
| Mineralys Therapeutics (MLYS) | 0.6 | $13M | +10% | 485k | 26.98 |
|
| Zenas Biopharma (ZBIO) | 0.6 | $13M | 502k | 25.38 |
|
|
| Ardelyx (ARDX) | 0.6 | $11M | -2% | 2.2M | 5.10 |
|
| Inspire Med Sys (INSP) | 0.5 | $11M | +85% | 244k | 44.61 |
|
| Bridgebio Pharma (BBIO) | 0.5 | $11M | +12% | 145k | 74.48 |
|
| Alkermes SHS (ALKS) | 0.5 | $11M | +8% | 200k | 52.40 |
|
| Summit Therapeutics (SMMT) | 0.5 | $10M | 715k | 14.57 |
|
|
| Brooks Automation (AZTA) | 0.5 | $10M | -29% | 403k | 25.52 |
|
| Indivior Pharmaceuticals (INDV) | 0.5 | $10M | +22% | 246k | 41.03 |
|
| Stryker Corporation (SYK) | 0.4 | $9.1M | +95% | 29k | 314.84 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.4 | $9.0M | 500k | 17.96 |
|
|
| Caris Life Sciences (CAI) | 0.4 | $8.7M | -13% | 488k | 17.82 |
|
| Omada Health (OMDA) | 0.4 | $8.2M | -31% | 373k | 21.95 |
|
| Compass Therapeutics (CMPX) | 0.4 | $7.7M | +6% | 3.5M | 2.19 |
|
| Immunome (IMNM) | 0.4 | $7.4M | 348k | 21.19 |
|
|
| Edap Tms S A Sponsored Adr (FOCL) | 0.4 | $7.2M | 1.4M | 5.18 |
|
|
| Phreesia (PHR) | 0.4 | $7.2M | +16% | 697k | 10.29 |
|
| Omeros Corporation (OMER) | 0.3 | $6.8M | NEW | 719k | 9.51 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.3 | $6.7M | NEW | 143k | 47.04 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.3 | $6.3M | +43% | 72k | 86.95 |
|
| Janux Therapeutics (JANX) | 0.3 | $5.6M | 367k | 15.36 |
|
|
| Mobia Med Common Stock | 0.3 | $5.6M | NEW | 418k | 13.40 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.3 | $5.5M | 180k | 30.83 |
|
|
| Thermo Fisher Scientific (TMO) | 0.2 | $5.0M | 10k | 501.36 |
|
|
| Trevi Therapeutics (TRVI) | 0.2 | $4.8M | NEW | 260k | 18.65 |
|
| Sionna Therapeutics (SION) | 0.2 | $4.4M | 99k | 43.99 |
|
|
| CVS Caremark Corporation (CVS) | 0.2 | $4.1M | 40k | 103.45 |
|
|
| Eyepoint Com New (EYPT) | 0.2 | $3.8M | +3% | 269k | 14.30 |
|
| Ocular Therapeutix (OCUL) | 0.2 | $3.8M | 384k | 9.82 |
|
|
| Spyre Therapeutics Com New (SYRE) | 0.2 | $3.8M | NEW | 42k | 88.78 |
|
| Talphera Com New (TLPH) | 0.2 | $3.7M | 3.6M | 1.03 |
|
|
| Roivant Sciences SHS (ROIV) | 0.2 | $3.6M | +4% | 101k | 35.39 |
|
| Vaxcyte (PCVX) | 0.2 | $3.5M | 60k | 58.13 |
|
|
| Neurogene (NGNE) | 0.2 | $3.4M | +2% | 107k | 31.45 |
|
| Century Therapeutics (IPSC) | 0.2 | $3.2M | 1.3M | 2.45 |
|
|
| Alphatec Hldgs Com New (ATEC) | 0.2 | $3.1M | +2% | 360k | 8.65 |
|
| Novo-nordisk A S Adr (NVO) | 0.1 | $3.0M | -29% | 64k | 47.94 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $2.9M | +38% | 235k | 12.51 |
|
| Nervgen Pharma Ord (NGEN) | 0.1 | $2.5M | NEW | 1.2M | 2.06 |
|
| Medtronic SHS (MDT) | 0.1 | $2.4M | NEW | 31k | 78.23 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.1 | $2.0M | +29% | 59k | 33.88 |
|
| Dianthus Therapeutics (DNTH) | 0.1 | $2.0M | -24% | 20k | 97.48 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $1.9M | NEW | 250k | 7.73 |
|
| Capricor Therapeutics Com New (CAPR) | 0.1 | $1.8M | NEW | 74k | 24.08 |
|
| Lenz Therapeutics (LENZ) | 0.1 | $1.5M | 258k | 5.68 |
|
|
| Altimmune Com New (ALT) | 0.1 | $1.4M | NEW | 472k | 3.04 |
|
| Kailera Therapeutics Common Stock | 0.1 | $1.4M | NEW | 65k | 22.03 |
|
| Surgery Partners (SGRY) | 0.1 | $1.4M | -59% | 84k | 16.80 |
|
| Axsome Therapeutics (AXSM) | 0.1 | $1.3M | NEW | 5.5k | 244.77 |
|
| Oruka Therapeutics (ORKA) | 0.1 | $1.1M | +192% | 12k | 95.17 |
|
| Viking Therapeutics (VKTX) | 0.0 | $995k | -73% | 26k | 39.01 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.0 | $968k | -17% | 34k | 28.88 |
|
| Glaukos (GKOS) | 0.0 | $664k | NEW | 4.8k | 139.76 |
|
| Jasper Therapeutics Com New (JSPR) | 0.0 | $463k | 1.1M | 0.42 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.0 | $221k | +75% | 22k | 10.00 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.0 | $208k | -82% | 11k | 19.47 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2026 Q2 filed Aug. 14, 2026
- Rock Springs Capital Management 2026 Q1 filed May 15, 2026
- Rock Springs Capital Management 2025 Q4 filed Feb. 17, 2026
- Rock Springs Capital Management 2025 Q3 filed Nov. 14, 2025
- Rock Springs Capital Management 2025 Q2 filed Aug. 14, 2025
- Rock Springs Capital Management 2025 Q1 filed May 15, 2025
- Rock Springs Capital Management 2024 Q4 filed Feb. 14, 2025
- Rock Springs Capital Management 2024 Q3 filed Nov. 14, 2024
- Rock Springs Capital Management 2024 Q2 filed Aug. 14, 2024
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022